Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bluebird Bio (BLUE – Research Report) and BeiGene (BGNE – Research Report).
Bluebird Bio (BLUE)
In a report released today, Gena Wang from Barclays maintained a Buy rating on Bluebird Bio, with a price target of $8.00. The company’s shares closed last Tuesday at $1.20, close to its 52-week low of $0.88.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $4.34, implying a 266.2% upside from current levels. In a report issued on March 18, Robert W. Baird also maintained a Buy rating on the stock with a $7.00 price target.
See the top stocks recommended by analysts >>
BeiGene (BGNE)
In a report released today, Rebecca Liang from Bernstein maintained a Hold rating on BeiGene, with a price target of $161.00. The company’s shares closed last Tuesday at $153.81, close to its 52-week low of $132.95.
According to TipRanks.com, Liang is ranked #7950 out of 8761 analysts.
Currently, the analyst consensus on BeiGene is a Strong Buy with an average price target of $251.31, implying a 61.1% upside from current levels. In a report issued on March 15, Bank of America Securities also reiterated a Hold rating on the stock with a $179.30 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BLUE:
